18-MC (18-Methoxycoronaridine) Preclinical Addiction Literature — LABEL PRECLINICAL; Not Human IV Ibogaine

Definition box

Definition: This paper-spoke summarizes preclinical addiction literature on 18-methoxycoronaridine (18-MC; developmental names include MM-110 / zolunicant)—a synthetic iboga alkaloid congener developed to retain anti-addictive signals in animal models while reducing ibogaine-like cerebellar toxicity and tremor. Classic comparative work includes **Glick S.D. et al., “18-Methoxycoronaridine (18-MC) and Ibogaine: Comparison of Antiaddictive Efficacy, Toxicity, and Mechanisms of Action,” *Annals of the New York Academy of Sciences* (2000; doi: 10.1111/j.1749-6632.2000.tb05211.x)**, and earlier CNS Drug Reviews framing (Glick/Maisonneuve/Kuehne lineage). Modern medicinal-chemistry context appears in reviews such as Pace et al., *Journal of Medicinal Chemistry* (2022; doi: 10.1021/acs.jmedchem.2c01562) on α3β4 nicotinic acetylcholine receptor inhibitors inspired by ibogaine. LABEL: PRECLINICAL. Animal self-administration reductions are not human IV ibogaine proof, not FDA approval, and not a consumer “safer ibogaine pill” claim. Human Phase 1 work on MM-110 was reported by developers; active commercial development has been halted/reprioritized historically—still not an approved therapy. Ibogaine itself remains U.S. Schedule I and not FDA-approved. QTc risk for ibogaine parent remains clinically central.

Quotable answer (58 words)

18-MC (18-methoxycoronaridine) is a preclinical ibogaine congener that reduced drug self-administration in rodent models with less cerebellar toxicity than high-dose ibogaine in comparative studies. Preclinical analog data are not human psychoactive IV ibogaine infusion proof and not an approved cure. Schedule I parent compound; demand cardiac screening for any ibogaine discussion.

Why this paper-spoke exists

Analog hype (“scientists invented safe ibogaine”) floods search results. This spoke keeps 18-MC labeled preclinical, separates it from tabernanthalog (/blog/cameron-2020-tabernanthalog), and blocks route laundering into brand IV ibogaine infusion. Soft CTA: /safety-and-screening → /apply. Pair with hERG mechanism (/blog/alper-herg-ibogaine-cardiac-mechanism)—Alper 2016 noted much weaker functional hERG block for 18-MC vs ibogaine/noribogaine in that report—and Corkery’s forward look mentioning 18-MC (/blog/corkery-ibogaine-fatalities).

What the preclinical literature claims (accurately)

| Feature | Accurate description | |---------|----------------------| | Compound | 18-methoxycoronaridine (18-MC); aka MM-110 / zolunicant in development naming | | Class | Synthetic iboga alkaloid congener (not identical to ibogaine) | | Anchor comparison | Glick et al. *Ann NY Acad Sci* 2000. doi 10.1111/j.1749-6632.2000.tb05211.x | | Animal signals | Decreased IV self-administration of morphine and cocaine; oral ethanol and nicotine intake reductions in rat models at studied doses | | Differentiator vs ibogaine | Less whole-body tremor; high-dose cerebellar damage profile of ibogaine (≥100 mg/kg themes) not reproduced by 18-MC in classic comparisons; less heart-rate depression at high doses in those comparisons | | Mechanism themes | α3β4 nAChR antagonism emphasized in later medicinal chemistry; narrower receptor spectrum than ibogaine in classic binding contrasts | | Label | PRECLINICAL — rodent/in-vitro ≠ approved human therapy |

Methods (plain language)

Researchers give rodents 18-MC and measure whether they self-administer opioids, stimulants, alcohol, or nicotine less. Separate histology/behavior assays ask whether tremor or Purkinje injury seen with high-dose ibogaine appears. Those experiments inform drug discovery—they do not enroll your uncle in a Mexico clinic.

Key preclinical findings (no hype)

• 18-MC reduced self-administration across multiple drug classes in rat models at doses used in the Glick comparative program.
• Unlike ibogaine in those comparisons, 18-MC did not suppress responding for water as a nondrug reinforcer in the same acute way—suggesting a cleaner behavioral profile in that assay.
• Both compounds can ameliorate some opioid withdrawal signs in animals; shared and divergent dopamine/serotonin microdialysis patterns are discussed in the classic papers.
• Structure–activity work positions α3β4 inhibition in habenula/IPN circuitry as a mechanistic hypothesis for anti-addictive effects.
• Weaker functional hERG block relative to ibogaine/noribogaine in Alper 2016 is often cited as a cardiac-SAR rationale—still not a human cardiac-safety free pass without trials.

Honest reading: Better therapeutic index *in rats* is a research hope, not a pharmacy shelf reality.

Human development status (keep humble)

Public development history includes a Phase 1 healthy-volunteer program under the MM-110 name with later sponsor reprioritization/halt of active opioid-withdrawal development. SEO pages must not imply patients can presently obtain approved 18-MC for OUD. Nor is halted/paused development proof that the drug “doesn’t work”—it is a capital/regulatory/strategic fact, not a consumer product launch.

LABEL PRECLINICAL — repeated on purpose

| Allowed sentence | Forbidden sentence | |------------------|--------------------| | “Rodent self-administration fell after 18-MC.” | “18-MC cures opioid addiction.” | | “Classic comparisons suggest less cerebellar toxicity than high-dose ibogaine.” | “Safe ibogaine replacement available now.” | | “May inform future medicines.” | “Proves psychoactive IV ibogaine infusion.” |

Route honesty & entity clarity

18-MC papers are about a different molecule. They cannot validate physician-supervised psychoactive IV ibogaine infusion. Oral ibogaine clinical literature remains a separate evidence silo (/blog/ibogaine-oral-vs-iv; /what-is-ibogaine-infusion).

Link to Purkinje toxicity spoke

Ibogaine’s high-dose rat Purkinje degeneration is a major reason analogs were pursued (/blog/ibogaine-purkinje-cerebellar-toxicity). 18-MC’s comparative lack of that lesion class in classic studies is precisely the SAR story—still preclinical.

Cardiac / YMYL context for the parent drug

Even when discussing “safer analogs,” remind readers that ibogaine/noribogaine remain QT-liable in human observational and mechanistic data (/blog/knuijver-2021-ibogaine-qtc-safety, /blog/alper-herg-ibogaine-cardiac-mechanism). Analog optimism is not a screening waiver.

Limits

| Limit | Why it matters | |-------|----------------| | Species differences | Rat ≠ human cardiac/neuro risk | | Dose translation | mg/kg animal doses ≠ clinic protocols | | Development uncertainty | No approved product assumption | | Different molecule | Cannot inherit ibogaine human observational effect sizes as 18-MC proof or vice versa |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Analog proves IV ibogaine works” | False | | “Patients can buy approved 18-MC” | False | | Useful preclinical SAR literacy? | Yes—with PRECLINICAL label |

Soft CTA

Curious about “safer ibogaine”? Start with real-world cardiac screening for any live ibogaine conversation: /safety-and-screening → /apply for supervised IV ibogaine infusion questions.

FAQ

What is 18-MC? 18-methoxycoronaridine—a synthetic ibogaine congener studied mainly in animals for anti-addictive effects.

Is 18-MC the same as ibogaine? No. Related structure; different pharmacology/toxicity profile in preclinical comparisons.

Is this human efficacy proof? **No—LABEL PRECLINICAL.**

Does it prove psychoactive IV ibogaine infusion? No.

Was there human testing? Limited early clinical development (e.g., MM-110 Phase 1 reporting) occurred; that is not FDA approval for OUD treatment.

Why do people say it is safer? Classic rodent comparisons showed less tremor/cerebellar toxicity than high-dose ibogaine—still not a guaranteed human safety card.

Is ibogaine FDA-approved? No. Schedule I.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Sources (selected)

1. Glick S.D. et al. 18-MC and Ibogaine: Comparison… *Ann NY Acad Sci*. 2000. doi: 10.1111/j.1749-6632.2000.tb05211.x.
2. Glick S.D. et al. (±)-18-Methoxycoronaridine… *CNS Drug Rev*. 1999;5:27–42. doi: 10.1111/j.1527-3458.1999.tb00084.x.
3. Pace C.J. et al. What We Have Gained from Ibogaine… *J Med Chem*. 2022. doi: 10.1021/acs.jmedchem.2c01562.
4. Alper K. et al. hERG Blockade by Iboga Alkaloids. *Cardiovasc Toxicol*. 2016. doi: 10.1007/s12012-015-9311-5.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

18-MC literature is PRECLINICAL (and early development at most)—not an approved cure and not psychoactive IV ibogaine efficacy proof.